BTK and B-cell chronic lymphocytic leukemia: While, novel therapies including treatment with ibrutinib, a Bruton's Tyrosine kinase (BTK) inhibitor, result in durable remissions in CLL, a proportion of patients still develop resistance to therapy [3].